What did @ninaaabrookeee actually say?
At week 8 of Mounjaro (tirzepatide), the creator claims the medication "really helped with my insulin resistance and also with my appetite suppression." She's on an unspecified starting dose, likely 2.5mg, and is considering moving to 7.5mg after an upcoming endocrinologist visit. She also mentions needing needles "to live," suggesting she may have type 1 or insulin-dependent type 2 diabetes. That context matters for evaluating her claims.
To her credit, she's not making wild promises. She's describing her own experience, checking in with a specialist before changing doses, and being transparent about the psychological burden of injection fatigue. That's more responsible than a lot of GLP-1 content on TikTok. But some of her framing still deserves a closer look.
Does the science back this up?
On appetite suppression: yes, robustly. On insulin resistance specifically: the evidence is real but more complicated than "this medication helped my insulin resistance" implies.
Tirzepatide works by activating both GIP and GLP-1 receptors, which together stimulate insulin secretion, suppress glucagon, and slow gastric emptying. The SURPASS clinical trial program showed significant reductions in HbA1c and fasting glucose across all doses. Ludvik et al. (2021, The Lancet) found tirzepatide at 5mg, 10mg, and 15mg produced HbA1c reductions of 1.87 to 2.07 percentage points versus 1.34 for semaglutide. A separate analysis by Dahl et al. (2022, Diabetes Care) found tirzepatide improved HOMA-IR, a standard proxy for insulin resistance, significantly compared to placebo.
So yes, there is clinical evidence that tirzepatide reduces markers of insulin resistance. The appetite suppression claim is also well-supported. Wilson et al. (2023, Nature Metabolism) demonstrated tirzepatide reduces energy intake partly through central appetite-suppressing mechanisms beyond just gastric emptying.
What did they get wrong (or right)?
She got more right than wrong. The two core claims, that Mounjaro helps with insulin resistance and suppresses appetite, are both supported by peer-reviewed data. She's not overstating a cure. She says it "really helped," which is personal and appropriately hedged.
What's worth flagging: the phrase "insulin resistance" is doing a lot of work here without much definition. Tirzepatide improves insulin sensitivity markers and reduces the compensatory hyperinsulinemia seen in type 2 diabetes and metabolic syndrome. But if she has type 1 diabetes (which the hashtags and her comment about needing injections "to live" suggest is possible), the mechanism and clinical picture are meaningfully different. GLP-1 agonists are used off-label in type 1 diabetes and can reduce insulin doses and improve glycemic variability, but they do not address the underlying autoimmune cause of insulin deficiency. Conflating insulin resistance with type 1 diabetes pathophysiology is a common and potentially misleading framing.
Her injection site preference, stomach over arm, is a legitimate practical tip backed by pharmacokinetic data showing abdominal subcutaneous tissue generally provides more consistent absorption.
What should you actually know?
If you're watching this video and thinking about whether Mounjaro might help your insulin resistance, here is what the evidence actually says. Tirzepatide is FDA-approved for type 2 diabetes (as Mounjaro) and for chronic weight management (as Zepbound). Clinical trials consistently show improvements in fasting insulin, HbA1c, and HOMA-IR. These are real, measurable effects, not anecdote.
But context is everything. Tirzepatide is not a standalone fix for insulin resistance. The SURMOUNT and SURPASS trials showed the best outcomes when combined with lifestyle changes. Dose escalation, like moving from a starting dose to 7.5mg, is standard protocol and should be guided by a prescriber, exactly as the creator describes. Do not adjust your own dose based on a TikTok video.
If you have type 1 diabetes, GLP-1 and dual GIP/GLP-1 agonists are not standard of care and carry specific risks including hypoglycemia when combined with insulin. Talk to an endocrinologist before starting.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a GLP-1 agonist only.
- Appetite suppression is one of its most documented effects in clinical trials.
- Insulin resistance improvements are measurable but depend on baseline metabolic status.
- Injection site does affect absorption. Abdomen is generally the most consistent site.
- Using GLP-1 class drugs in type 1 diabetes is off-label and requires specialist oversight.